Neurocrine’s 2026 Guidance Now at Risk as Q1 Pricing Pressure Tests Stock’s Execution Conviction

The core news is a positive one for Neurocrine. Earlier this month, the company presented two key developments at a long-term care conference. First, a multidisciplinary expert panel released structured consensus recommendations for screening and treating tardive dyskinesia in older adults. Second, Neurocrine shared post-hoc KINECT-PRO™ analysis showing clinically meaningful patient-reported improvements in TD impact with INGREZZA in adults aged 65+. This data directly reinforces the new guidelines, aiming to deepen INGREZZA's clinical relevance in a high-risk geriatric population.

Yet the market's reaction tells a different story. Despite this supportive data, the stock has pulled back significantly, with shares down 16.6% over the past three months. This move comes on the heels of a clear earnings miss, where the company reported non-GAAP EPS of $1.88 against a consensus expectation of $2.31 for Q4 2025. The thesis here is that the new geriatric data, while valuable, is likely already priced in. The stock's recent weakness is driven more by near-term commercial execution risks and the tangible impact of that earnings disappointment, overshadowing the longer-term opportunity.

Viewed through the lens of expectations, this is a classic case of good news being insufficient to overcome a reset in near-term fundamentals. The data strengthens the bull case for INGREZZA's future, but the market is currently focused on the whisper number for the next quarter, which appears to have been missed. The pullback suggests investors are looking past the positive clinical narrative to the more immediate pressures of pricing and profitability.

Commercial Reality: Guidance vs. Execution

The new geriatric data is a long-term narrative win, but it does not change the near-term financial setup. For 2026, the market is focused squarely on execution against a clear, known path. Management has laid out a straightforward commercial trajectory: Ingrezza is guided to $2.7–$2.8 billion in revenue, a step up from its $2.51 billion in 2025. This growth, however, comes with a built-in price headwind. The company forecasts a ~4–5% blended year-over-year price decline for the full year, driven by expanded access and contractual dynamics. The real near-term pressure point is the first quarter, where a larger ~10% Q1 net price-per-script drop is expected before a gradual recovery into the second half.

This is the expectation gap investors are weighing. The guidance itself is not a surprise; it was reiterated after the earnings miss. The tension lies in the execution required to hit it. Management plans to leverage improved access and a sales force expansion expected to be "live in Q2" to drive volume growth and offset pricing. Yet, the stock's pullback suggests skepticism about the company's ability to navigate this quarter's steep price decline smoothly. The market is looking past the positive clinical data to the tangible, quarterly pressure of managing net prices.

Adding to the diversified growth story is CRENESSITY, which generated $300 million in its first commercial year and captured roughly 10% of its market. This early traction is a positive, but it remains a small contributor to the overall revenue mix. The core of the 2026 thesis remains Ingrezza's ability to deliver on its guidance despite the known pricing headwinds. The geriatric data strengthens the long-term TAM, but the near-term financial outlook is defined by this quarterly price vs. volume battle.

The Pipeline Catalyst and Valuation Gap

The market is effectively trading two different Neurocrine stories. The near-term narrative is one of execution, defined by the quarterly price vs. volume battle for Ingrezza. The forward-looking story, however, is a "data-rich" 2027, with multiple mid- and late-stage readouts expected. This creates a clear valuation gap: is the stock priced for the known 2026 grind, or the potential catalysts of 2027?

Analyst consensus leans toward the latter. The stock carries a "Moderate Buy" rating with an average price target implying roughly 23% upside from recent levels. That target, however, sits on a wide range from $115 to $203, highlighting deep uncertainty. The high end of that range clearly prices in a successful 2027 data cascade, while the low end likely reflects skepticism about navigating the near-term commercial headwinds.

The key risk to that optimistic path is the Inflation Reduction Act (IRA). Management says it can manage the impact, citing Teva's Austedo Medicare fair-price as a reference point. Austedo's Medicare fair-price landed ~38% below its 2024 WAC, a stark reminder of the pricing pressure at play. Neurocrine is actively negotiating Medicare placements for 2027, but the outcome remains a wildcard that could significantly affect the profitability of its core asset, Ingrezza, even as the pipeline advances.

The bottom line is that 2026 is a year of waiting. The stock's pullback suggests the market is focused on the execution risks of hitting that $2.7–$2.8 billion Ingrezza guidance while managing a steep Q1 price decline. The 2027 data catalysts are real, but they are still a year away. For now, the valuation reflects a bet on smooth execution, not a data-driven pop. Any stumble in the near-term commercial plan could quickly reset expectations downward, making the wide analyst target range a warning sign rather than a roadmap.

Catalysts and Risks: What to Watch

The stock's path forward hinges on a few clear, near-term events that will either validate the execution plan or expose its vulnerabilities. The immediate focus is on the first quarter, where the market will see the direct impact of the larger ~10% Q1 net price-per-script drop. The key metric to watch is whether volume growth from the planned salesforce expansion and improved access can fully offset this steep decline. Any stumble here would confirm the worst fears about the commercial grind and likely trigger another sell-off.

Beyond the quarterly numbers, the critical lever for long-term pricing power is the outcome of Medicare negotiations. The company is actively working on placements for 2027, a move that will define the new baseline for Ingrezza's profitability. The reference point is clear: Teva's Austedo Medicare fair-price landed ~38% below its 2024 WAC. If Neurocrine's own 2027 Medicare price is similarly punitive, it would pressure margins and make hitting the $2.7–$2.8 billion revenue target more difficult. Conversely, a better outcome would be a major positive surprise.

Then there is the long-term catalyst. The entire "data-rich" 2027 narrative is priced in at some level. Multiple mid- and late-stage readouts are expected, including phase III results for osavampator and direclidine. Any delay or negative result from these programs would reset expectations downward, likely pulling the stock back toward the lower end of the wide analyst price target range. The primary risk is not the geriatric data already presented, but the execution of the commercial plan in 2026 and the success of the pipeline in 2027. The stock will re-rate based on which story proves more real.